Alcon launches the CyPass Micro-Stent at the American Academy of Ophthalmology (AAO) 2016 annual meeting

Alcon to host first live training program on the use of the CyPass Micro-Stent, a minimally invasive glaucoma surgical device to treat cataract patients with mild to moderate primary open-angle glaucoma. Two-year safety and efficacy data from landmark COMPASS study published in peer reviewed journal Ophthalmology ; data reinforcing intraocular pressure (IOP)-lowering benefits of the CyPass Micro-Stent to be presented at conference The digital press release with multimedia content can be accessed here: - Alcon, the global leader in eye care and a division of Novartis, announced the US launch of the CyPass Micro-Stent at the annual meeting of the American Academy of Ophthalmology (AAO), October 15-18 in Chicago, where Alcon will host a live training program and present additional data during poster and oral sessions. The CyPass Micro-Stent was approved by the US Food and Drug Administration in July for use in conjunction with cataract surgery to lower intraocular pressure in adult patients with mild to moderate primary open-angle glaucoma. "We are excited to launch the CyPass Micro-Stent device in a new segment of glaucoma treatment called minimally-invasive glaucoma surgery, or MIGS," says Sergio Duplan, Region President, North America, Alcon. "This new treatment option for cataract patients with mild to moderate primary open-angle glaucoma has been demonstrated to have a lasting, significant IOP-lowering effect." The CyPass Micro-Stent device is implanted during cataract surgery, just below the surface of the eye, into the supraciliary space.